Treatment
Tepotinib clinical trials
We’re tracking 7 recruiting studies that include Tepotinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06106802RecruitingPhase 2
Testing lazertinib and tepotinib for EGFR lung cancer that progressed on lazertinib
This trial tests a combination of two targeted drugs, lazertinib and tepotinib, for people with advanced EGFR-mutant non-small cell lung cancer whose tumors show MET overactivity (high MET levels or MET gene copies) and have grown despite prior treatment with lazertinib. It aims to see if adding tepotinib can overcome that resistance.
Seoul, Gangnam-guAges 19 years+ - NCT05439993RecruitingPhase 1/Phase 2
Tepotinib plus paclitaxel for MET-altered stomach cancer
This trial tests whether tepotinib combined with paclitaxel can treat stomach or gastroesophageal (GEJ) cancer that has spread and has specific MET gene changes. It may help by blocking the MET pathway that can drive tumor growth after standard chemotherapy.
Gyeonggi-doAges Any age - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT07619339RecruitingPhase 1
Tepotinib and Ivonescimab for MET-Driven Lung Cancer
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Daphne, AlabamaAges 18 minutes+ - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+
What Tepotinib is being studied for
Conditions with recruiting Tepotinib studies.
Common questions
- Are there clinical trials studying Tepotinib?
- Yes. Clin2 currently lists 7 recruiting studies that include Tepotinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tepotinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tepotinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tepotinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.